Y-mAbs Therapeutics confirmed BLAs on track for this year – HBM Healthcare-portfolio company Y-mAbs Therapeutics (Nasdaq: YMAB) has confirmed it remains on target to file regulatory submissions for both of its rare paediatric cancer products this year. The company confirmed it is on track to file for omburtamab for the treatment of CNS/LM from neuroblastoma, […]
Gilead confirms plan to file filgotinib this year – Trust favourite Gilead (NASDAQ: GILD) announced yesterday that it expected to file its closely watched JAK1 inhibitor filgotinib – which is licensed from the Belgian biotech Galapagos (NASDAQ:GLPG) – in the key indication of rheumatoid arthritis (RA) later this year, up to 12 months ahead of the […]
Sareum raises £0.8m to advance TYK2/JAk1 programmes Sareum Holdings (SAR) has raised £0.78m through a placing of 195m shares at 0.4p per share, in a move principally designed to progress its TYK2/JAK1 programmes. As a result of the placing, the company will have 3.07bn shares in issue. The funds Sareum to advance its internal programmes – SDC-1801 […]
AbbVie to buy Allergan in a $63bn deal US pharma giant AbbVie is to acquire the US-based, but Irish-domiciled speciality pharma Allergan, in a cash-and-share deal with an equity value of $63bn. he transaction is designed to expand and diversify AbbVie’s revenue base into new therapeutic areas, including what is termed medical aesthetics – Allergan […]
BMS’s plan to dispose of Otezla puts focus on putative TYK2i class Bristol-Myers Squibb has announced plans to divest the anti-inlammatory drug Otezla (apremilast) – which it would ostensibly obtain in its pending merger with Celgene – seemingly to allay anti-trust concerns over new oral treatments for psoriasis. The move is likely to be of […]
Trust favourite Vertex holds industry’s most valuable R&D asset Investment trust favourite Vertex Pharmaceuticals (Nasdaq: VRTX) holds the pharma/biotech industry’s most valuable R&D asset, according to calculations from the industry consultancy Evaluate. The US firm’s triple therapy of VX-445/tezacaftor/ivacaftor, which is in Phase III studies for cystic fibrosis and on track for a launch next […]
Incyte details positive outcome of topical rux in vitiligo Trust favourite Incyte (Nasdaq:INCY) saw its stock rise by 5% today after reporting positive results of a Phase II study of ruxolitinib cream in the treatment of vitiligo (a condition characterised by de-pigmentation of skin) at a scientific conference over the weekend. Incyte, which is held by […]
Trust favourite Array acquired by Pfizer US cancer focussed biotech Array BioPharma (NASDAQ: ARRY) has accepted a $48 per share cash takeover offer from Pfizer, a 62% premium of its closing price on Friday and equivalent to an enterprise value of $11.4bn (market cap less net cash). Array, whose stock rose by 56% this morning, […]
Biotech firms brace for wave of Woodford fund liquidations Arix Biosciences (ARIX), Reneuron (RENE), Mereo Biopharma (MPH) and 4D Pharma (DDDD) look set to be among the firms braced for the potential sale of all or parts of the shareholdings held by Woodford Invesmtent Management in the coming days, as the troubled manager appears to […]
InflaRx stock crashes on study failure in HS US-listed German biotech InflaRx (Nasdaq: IFRX) saw its stock fall by 89% earlier today on the failure of a Phase IIb study of its lead product, IFX-1, in moderate to severe hidradenitis suppurativa (HS), a painful and chronic inflammatory skin disease. The study enrolled 179 patients who […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated